Gujarat-based manufacturer of cellulose-based pharmaceutical excipients — MCC, SMCC, CCS and Magnesium Stearate — exported to 75+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 4 | 4 | 13 | 13 | 21 | 21 | 24 | 24 |
| Reserves | 21 | 22 | 19 | 37 | 143 | 174 | 226 | 252 |
| Borrowings | 30 | 31 | 24 | 23 | 13 | 2 | 1 | 1 |
| Other Liabilities | 22 | 23 | 38 | 37 | 28 | 32 | 38 | 45 |
| Total Liabilities | 77 | 81 | 95 | 111 | 205 | 228 | 289 | 322 |
| AssetsFixed Assets | 29 | 30 | 30 | 31 | 29 | 48 | 50 | 53 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 13 | 41 | 102 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 48 | 50 | 64 | 79 | 174 | 168 | 198 | 167 |
| Total Assets | 77 | 81 | 95 | 111 | 205 | 228 | 289 | 322 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 6 | 5 | 5 | 15 | 8 | 11 | 25 | 19 |
| Cash from Investing | -4 | -2 | -6 | -4 | -4 | -82 | -9 | -49 |
| Cash from Financing | -1 | -2 | -2 | -10 | -4 | 72 | -14 | 36 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | 3 | 0 | 11 | 3 | -2 | -12 | -68 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (8.7×) and current (14.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 9× exit, ₹452 only delivers your return if you pay ₹200. The price is currently baking in 27% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 9×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 35.27 |
| FY28 | 10.0% | 38.79 |
| FY29 | 10.0% | 42.67 |
| FY30 | 10.0% | 46.94 |
| FY31 | 10.0% | 51.63 |
| FY32 | 8.0% ·fade | 55.76 |
| FY33 | 6.0% ·fade | 59.11 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.